Evaluating the Efficacy of a Gum Health Formulation on Teeth Whitening in Patients With Gingivitis and Periodontitis
A Randomized Trial Evaluating the Efficacy of a Gum Health Formulation on Teeth Whitening in Patients With Gingivitis and Periodontitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- EEC Institute, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to read, understand and sign an Informed Consent form
- Good general health as evidenced by the medical history
- Between 18 and 65 years of age
- A minimum of 20 teeth, excluding crowns and third molar teeth
- A mean whole mouth Gingival Index score of >2.0 at baseline
- Sites with <7mm pocket depth
- Willing to abstain from all oral hygiene procedures for 12-18 hours prior to clinical visits
- Willing to abstain from eating and drinking in the morning of visits, only drinking water
- Willing to abstain from chewing gums, oral whitening products, mouthwashes and tobacco products for the study duration
- Ability to understand and follow study protocol
- No known history of allergy to dairy products or their ingredients, relevant to any ingredient in the test products
Exclusion Criteria:
- Chronic use of photosensitizing medications including NSAIDs, antidepressants, antibiotics and beta blockers
- Diagnosis of diabetes mellitus
- Presence of orthodontic appliances
- Presence of large restorations
- Crown or veneer at the anterior of both upper and lower teeth (including premolar teeth)
- A soft or hard tissue tumor of the oral cavity
- Carious lesions
- Severe internal (tetracycline stains) and external discolouration (fluorosis)
- Diagnosis of severe chronic periodontitis, aggressive periodontitis, acute necrotizing ulcerative gingivitis or generalized gingival recession >2mm as evidenced by clinical oral exam
- Participating in another clinical trial or oral product study
- Pregnant or breast-feeding women
- Allergy to home bleaching products such as hydrogen peroxide and carbamide peroxide
- Use of antibiotics within 3 months of enrolment
- History of drug use that is associated with gum overgrowth (i.e., Dilantin, nifedipine, etc.)
- Chronic use of medication such as steroids, anti-coagulant medications, immunosuppressant medications or any other medications or medical conditions that in the opinion of the investigator would interfere with the evaluation or confound interpretation of the study results
- Medical condition which requires pre-medication prior to dental visits/procedures
- Smokers
- Patients who have received quadrant or maintenance scaling & root planing and/or periodontal surgical therapy within 6 months prior to enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Gum health formulation in intra-oral device
The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily.
Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
|
The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
Other Names:
|
|
Experimental: Gum health formulation on toothbrush
The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
|
The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
Other Names:
|
|
No Intervention: Control group (split-mouth design)
The control group did not receive the interventional gum health formulation.
Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline Tooth Shade Value over 45 Days
Time Frame: Baseline, Day 14, Day 28, Day 45
|
Tooth Shade Value was measured using a Vita Shade Guide and the measurement was transformed to a standardized value.
|
Baseline, Day 14, Day 28, Day 45
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plaque Index
Time Frame: Baseline, Day 14, Day 28, Day 45
|
Periodontal probe will be swept along the buccal and lingual surfaces and plaque is noted.
|
Baseline, Day 14, Day 28, Day 45
|
|
Gingival Index
Time Frame: Baseline, Day 14, Day 28, Day 45
|
Periodontal probe will be placed under the gingival margin and swept along the buccal and lingual surfaces and bleeding is noted.
|
Baseline, Day 14, Day 28, Day 45
|
|
Bleeding Index
Time Frame: Baseline, Day 14, Day 28, Day 45
|
Bleeding will be assessed after probing.
A dichotomous scoring system is used at six sites per tooth using one and zero for presence or absence, respectively.
|
Baseline, Day 14, Day 28, Day 45
|
|
Mean Probing Depth
Time Frame: Baseline, Day 14, Day 28, Day 45
|
Pocket depth will be determined with a UNC-15 periodontal probe at six sites per tooth rounded to the next lower whole millimeter.
|
Baseline, Day 14, Day 28, Day 45
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Edgard El Chaar, DDS, MS, EEC Institute, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GLO-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.